Please ensure Javascript is enabled for purposes of website accessibility

Why Agile Therapeutics Stock Jumped Today

By Keith Speights - Feb 11, 2020 at 3:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.

What happened

Shares of Agile Therapeutics (AGRX 10.44%) were jumping 8.5% higher as of 3 p.m. EST on Tuesday after rising as much as 15.7% earlier in the day. The big gain came after the drugmaker announced that it had entered into a loan credit facility with Perceptive Advisors that will provide Agile with up to $35 million.

Agile received $5 million in the first tranche of this credit facility. The company will be able to receive another $15 million if hormonal contraceptive patch Twirla wins approval from the U.S. Food and Drug Administration (FDA). The final $15 million in the loan will become available once Agile achieves specified revenue milestones.

Businessman in suit handing over money

Image source: Getty Images.

So what

Investors liked Agile's loan agreement for a couple of key reasons. Most importantly, the deal provides much-needed cash to the company. At the end of September 2019, Agile had $18.4 million in cash and cash equivalents. The loan credit facility with Perceptive Advisors enables Agile to avoid having to issue new shares to raise more capital, a move that would have diluted the value of existing shares.

The other nice thing about the loan credit facility is that Agile can make interest-only payments until February 2023. This helps stretch out the company's cash for enough time that it should have solid revenue coming in, assuming the FDA approves Twirla.

Now what

By far, the most important thing for investors to watch with Agile is what happens with Twirla. In November, the FDA pushed back its date for a decision on the contraceptive until Feb. 16, 2020. An approval for Twirla would likely cause the pharmaceutical stock to soar even more than it did today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agile Therapeutics, Inc. Stock Quote
Agile Therapeutics, Inc.
$1.27 (10.44%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.